Yes. Alzheimer's disease is progressive by definition and the changes continue over years. What varies widely is the pace, which is difficult to predict at diagnosis. Two newer antibody therapies slow decline in early disease; neither halts it, and neither restores what has already been lost.
Yes. Alzheimer's disease is progressive by definition and the changes continue over years. What varies widely is the pace, which is difficult to predict at diagnosis. Two newer antibody therapies slow decline in early disease; neither halts it, and neither restores what has already been lost.
The typical sequence begins with difficulty forming new memories, because the medial temporal structures are affected early. Word-finding, orientation in time and place, handling money, following multi-step tasks and recognising familiar routes follow as more cortex is involved. Behaviour and sleep often change later. Published stages are descriptive shorthand, not a timetable, and people do not move through them at a uniform rate or in an identical order. Two people with the same test scores can have quite different day-to-day capability, which is why function is assessed alongside cognition.
The honest answer is that the pace is measured in years and cannot be forecast precisely for an individual. Some people change little across a couple of years; others decline noticeably within one. Younger onset and mixed pathology, particularly coexisting cerebrovascular disease, are associated with faster progression in published series. Sudden deterioration over days or weeks is not how Alzheimer's disease behaves, and it should prompt a search for something else: infection, a new medication, dehydration, delirium or a stroke.
Cholinesterase inhibitors and memantine are symptomatic. They can produce a modest improvement in cognition and function for a period, and they do not alter the underlying disease. The anti-amyloid monoclonal antibodies are different in kind: in early symptomatic disease they slow the rate of decline. They do not stop it, they do not reverse existing loss, they require confirmation of amyloid pathology beforehand, and they carry a risk of brain swelling and small haemorrhages that has to be monitored with repeated MRI.
This practice diagnoses and follows cognitive disorders, reviews medication, and manages the neurological side of care for adults 18 and older. It operates no infusion suite and no imaging suite. Anti-amyloid therapy requires regular infusions and scheduled MRI surveillance, so where it is appropriate the treatment itself is arranged with a service equipped to deliver and monitor it. MRI, CT and lumbar puncture are performed at an imaging centre or hospital, with the report reviewed with you here.
Clinical Neurology Specialists has been physician-owned since 1998, when Leo Germin, M.D., FAANEM founded it. Five board-certified neurologists and four advanced practice providers see patients at the Las Vegas and Henderson offices, each with its own AANEM-accredited electrodiagnostic laboratory.
Clinical Neurology Specialists is an adult outpatient neurology practice for patients 18 and older. The practice performs no surgery and operates no imaging suite, infusion suite or interventional pain programme, and provides no emergency or inpatient care.
Physician-reviewed. Reviewed by the physicians of Clinical Neurology Specialists — board-certified neurologists, AANEM-accredited electrodiagnostic laboratories, physician-owned since 1998. Reviewed 1 August 2026. This article is general education for adults 18 and older and is not a substitute for a consultation.
Sources and further reading: MedlinePlus: Alzheimer disease; National Institute on Aging: Alzheimer's treatment; National Institute on Aging.
Adults 18 and older, at the Las Vegas and Henderson offices. Call 702-804-1212 or request an appointment online.